Evidence map›Paper›PMID 39261850›Full record

ArticleOrphanet journal of rare diseases2024

Epidemiology of Wilson disease in Germany - real-world insights from a claims data study.

Shona Fang, Peter Hedera, Julia Borchert, Michael Schultze, Karl Heinz Weiss

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shona FangAlexion, AstraZeneca Rare Disease, 121 Seaport Avenue, Boston, 02210, MA, USA. shona.fang@alexion.com.
Peter HederaUniversity of Louisville, Louisville, KY, USA.ORCID 0000-0003-2699-4085
Julia BorchertScientific Institute for Health Economics and Health System Research (WIG2 GmbH), Leipzig, Germany.
Michael SchultzeBerlin Center for Epidemiology and Health Research, ZEG Berlin GmbH, Berlin, Germany.
Karl Heinz WeissSalem Medical Center, Heidelberg, Germany.

Funding

Alexion Pharmaceuticals Alexion Pharmaceuticals
6 · The paper itself

Abstract

backgroundWilson disease (WD) is a rare disorder of copper metabolism, causing copper accumulation mainly in the liver and the brain. The prevalence of WD was previously estimated around 20 to 33.3 patients per million for the United States, Europe, and Asia, but data on the prevalence of WD in Germany are limited.

objectivesTo describe patient characteristics and to assess prevalence of WD in Germany using a representative claims database.

methodsWD patients were identified in the WIG2 (Wissenschaftliches Institut für Gesundheitsökonomie und Gesundheitssystemforschung; Scientific Institute for Health Economics and Health Systems Research) benchmark database of 4.5 million insured Germans by combining ICD-10-coding with WD-specific lab tests and treatments. The study period ranged from 2013 to 2016 for assessing patient characteristics, and to 2018 for prevalence, respectively.

resultsSeventy unique patients were identified. Most patients (86%) were between 18 and 64 years of age and more often male (60%) than female. Two patients (3%) younger than 18 years were included, as well as 8 patients (11%) older than 64 years. Most common WD subtypes were hepatic (57%), psychiatric (49%), and neurologic (44%). Average prevalence was 20.3 patients per million (range: 17.8-24.4), with similar results for two-year prevalence. Generally, prevalence increased steadily over the study period. Observed mortality was low, with only one death during the study period.

conclusionsThis study adds valuable real-world data on the prevalence and patient characteristics of WD in Germany. Generally, our findings align with other reports and contribute to the global understanding of WD epidemiology. Still, regional and temporal trends remain to be investigated more thoroughly to further the understanding of the natural history and epidemiology of this rare disease.

Indexed as

Hepatolenticular DegenerationAdolescentAdultAgedChildDatabases, FactualFemaleGermanyHumansMaleMiddle AgedPrevalenceYoung AdultClaims dataEpidemiologyPrevalenceReal-world evidenceWilson disease

Identifiers

PMID39261850
PMCPMC11391731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.